Unsaturated mTOR inhibitors
Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
1. A compound represented by Formula (I)
or a pharmaceutically acceptable salt thereof, wherein:
X 1 and X 2 are both CH;
X 4 , X 6 , and X 7 are all C;
X 3 and X 5 are both N;
R 3 is cycloC 3-10 alkyl or heterocyclyl, either of which is optionally substituted by —C(O)O(CH 2 ) aa hetaryl, —C(O)(CH 2 ) aa hetaryl, —C(O)O(CH 2 ) aa aryl, —C(O)(CH 2 ) aa aryl, or —C(O)OC 0-6 alkyl;
Q 1 is —A—(K) m
A is vinyl or acetylenyl
K is aryl or hetaryl, either optionally substituted by halogen;
m is 1;
aa is 0 or 1; and
provided that the compound is not
3-cyclobutyl-1-[(4-phenoxyphenyl)ethynyl]imidazo[1,5-a]pyrazin-8-amine, 3-cyclobutyl-1-[(1-methyl-1H-imidazol-5-yl)ethynyl]imidazo[1,5-a]pyrazin-8-amine, N-{3-[(8-amino-3-cyclobutylimidazo[1,5-a]pyrazin-1-yl)ethynyl]phenyl}-4-chlorobenzamide or 3-cyclobutyl-1-(pyridin-4-ylethynyl)imidazo[1,5-a]pyrazin-8-amine.
2. The compound according to claim 1 , selected from
or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.